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Abstract
Introduction
Progress with the treatment of cutaneous leishmaniasis (CL) has been hampered by
inconsistent methodologies used to assess treatment effects. A sizable number of trials
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conducted over the years has generated only weak evidence backing current treatment
recommendations, as shown by systematic reviews on old-world and new-world CL
(OWCL and NWCL).
Materials and methods
Using a previously published guidance paper on CL treatment trial methodology as the refer-
ence, consensus was sought on key parameters including core eligibility and outcome
measures, among OWCL (7 countries, 10 trial sites) and NWCL (7 countries, 11 trial sites)
during two separate meetings.
Results
Findings and level of consensus within and between OWCL and NWCL sites are presented
and discussed. In addition, CL trial site characteristics and capacities are summarized.
Conclusions
The consensus reached allows standardization of future clinical research across OWCL and
NWCL sites. We encourage CL researchers to adopt and adapt as required the proposed
parameters and outcomes in their future trials and provide feedback on their experience.
The expertise afforded between the two sets of clinical sites provides the basis for a power-
ful consortium with potential for extensive, standardized assessment of interventions for CL
and faster approval of candidate treatments.
Author summary
The term ‘cutaneous leishmaniasis’ (CL) includes a range of manifestations affecting the
skin caused by Leishmania parasites across several continents. While not life-threatening,
CL can be invalidating and disfiguring, or become complicated. Today, there is no satis-
factory treatment for CL that is effective and safe. Faced with no investments into develop-
ing drugs for CL, clinical researchers have tried many treatments over the years, but little
progress has been made. One of the reasons is the lack of standardized methodologies in
conducting these trials which makes it difficult to collate and compare results. Clinical
researchers now realize that their efforts can be brought to fruition if common methodol-
ogies are available and applied. This paper summarizes the principles and parameters
agreed upon by researchers of how to identify patients and how to measure treatment
effects in a way that will make it possible to gather convincing evidence of whether a treat-
ment works or not. Adhering to these principles will allow faster progress towards offering
better care to patients with this neglected disease.
Introduction
Cutaneous leishmaniasis (CL) is a disease caused by various Leishmania species affecting an
estimated 0.7–1.2 million people each year in the Americas, the Mediterranean basin, the Mid-
dle East and Central Asia. In 2013, 95% of the cases reported to WHO occurred in 15 coun-
tries: Afghanistan, Algeria, Brazil, Colombia, Honduras, Iran (Islamic Republic of), Morocco,
Clinical trial methodologies for CL
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006141 January 12, 2018 2 / 12
publication and it does not necessarily represent
the decisions, policy, or views of the WHO.
Remaining authors have declared that no
competing interests exist.
Nicaragua, Pakistan, Peru, Saudi Arabia, Syrian Arab Republic, Tunisia, Turkey, and Yemen
[1,2]. In 2014, over 153 000 cases were reported to WHO from 10 high-burden countries [3,4].
Progress with the treatment of CL has been hampered by lack of investments in drug dis-
covery and development, but also by the inconsistent methodologies that have been used to
assess treatment effects [5]. This has resulted in significant scientific and financial waste, as a
sizable number of trials conducted over the years have generated only weak evidence for treat-
ment recommendations.
These weaknesses were exposed by two Cochrane systematic reviews on Old-World [6]
and New-World [7] CL (OWCL and NWCL; the latter recently updated [8]). To correct these
shortcomings, a series of steps were set in place towards achieving consensus on the main
parameters that would help establish standardized, generally adoptable criteria in clinical
investigations. This process started with a consultation jointly organized by the Special Pro-
gramme for Research and Training in Tropical Diseases (WHO/TDR) and the World Health
Organization Programme for Leishmaniasis at the Neglected Tropical Diseases Department
(WHO/NTD) held in 2009, which led to a guidance paper in 2013 [9] that aimed to (i) provide
clinical investigators with guidance for the design, conduct, analysis and report of clinical trials
of treatments for CL, whilst recognizing the complexity of the disease; and (ii) enhance the
capacity for high-quality trials that fulfil the requirements of International Conference on
Harmonization (ICH) and Good Clinical Practice (GCP) standards.
A network of clinical trial sites for NWCL (RedeLeish [10]) was started with support by the
Drugs for Neglected Diseases initiative (DNDi) in 2014, and discussions are underway to
extend this network to OWCL (jointly with TDR).
Methods
Basic parameters from the above-mentioned guidance paper were submitted to a group of
OWCL and NWCL clinical trialists and discussed at workshops that took place in Tunisia
(February 2016, hosted by the TDR regional training centre at Institute Pasteur, Tunis and
organized by TDR) and in Brazil (June 2016, organized by DNDi). The meetings were
attended by expert CL trialists representing 10 clinical study sites from 7 OWCL countries
(Afghanistan, Burkina Faso, Ethiopia, Iran (Islamic Republic of), Morocco, Tunisia and Tur-
key) and 11 clinical study sites from 7 NWCL countries (Bolivia, Brazil, Colombia, Guatemala,
Panama, Peru and Venezuela).
Results
Consensus on key methodological issues in clinical trials of CL treatments
The degree of consensus and main issues are summarized in Table 1 for OWCL and NWCL,
along with the revised parameters after the two above mentioned consultations. A diagram-
matic representation can be found in Fig 1.
As for eligibility criteria, it was agreed that parasitological confirmation by visualization of
the parasite (amastigotes in smears, promastigotes in culture) or molecular biology testing
(primary PCR) is required for a patient to be enrolled in clinical trials; Leishmania species
identification is not required for enrolment but is required for data analysis. The need for base-
line safety tests (hematology, liver and renal function) depends on the risks associated with the
treatment (route of administration and the phase of development), the drug’s chemical class,
and the perceived or known liabilities of the treatment (expected toxicity).
As for the efficacy parameters, there was consensus about re-epithelization for ulcerated
lesions and flattening for non-ulcerated lesions as primary efficacy measures. The majority of
Clinical trial methodologies for CL
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participants was for adding absence of induration as an efficacy parameter (though more diffi-
cult to standardize), while redness (inflammation) was thought to be not sufficiently reliable.
Even though the natural history and treatment response vary across the range of old and
new world Leishmania species, it was agreed that initial cure should be assessed at Day 90–100
(Day 0 being the day of enrolment and Day 1 being the first day of treatment) since it provides
the best chances to assess success or failure. In OWCL treatment trials, an additional earlier
assessment at Day 42 should also be conducted and reported to capture the earlier clinical
response observed in these species.
In addition, OWCL participants identified the need to document more clearly and quantify
the rate of self-healing in L. major, in order to better inform decisions on follow-up and study
design, such as the assessment of time-to-heal particularly after topical treatment, as a second-
ary outcome—which would require multiple assessments. NWCL participants discussed the
need to collect evidence towards a future definition of “early failure” (before Day 42) based on
the type of intervention/treatment being evaluated.
Table 1. Agreement on key parameters by OWCL and NWCL clinical researchers. ‘Standardized’ criteria are those as proposed in the reference paper Olliaro et al,
20139; ‘updated’ criteria are those resulting from the consultation.
Key Parameters Standardised
(Olliaro et al, 2013)9
OWCL
10 sites, 7
countries
NWCL
11 sites, 7
countries
Updated
Yes No Yes No
Eligibility criteria
Only parasitologically-confirmed cases can be enrolled Yes 100% 100% Yes
Leishmania species identification required for enrolment Yes/No 100% 100% No
Leishmania species identification required for analysis Yes/No 100% 100% Yes
Baseline safety tests required (haematology, liver and renal function) Yes/No 100% 100% Yes
Efficacy parameters
Re-epithelization of ulcerated lesions Yes 100% 100% Yes
Flattening of non-ulcerated lesions Yes 100% 100% Yes
Induration No 80% 91% (Yes)
Redness No 100% 100% No
Time at which initial cure should be assessed
End of treatment No 100% 100% No
Day 42 Yes 100% 100% Yes OW; No NW
Day 90 Yes 100% 100% Yes
Time at which final cure should be assessed
Day 180 (6 months) Yes 100% 100% Yes
Day 360 (12 months) Yes/No 100% 100% No
Follow-up counting from when?
From the end of treatment No 100% 100% No
From the beginning of treatment Yes 100% 82% (Yes)
Definition of treatment failure
Day 42: <50% re-epithelization (ulcer) or flattening (non-ulcerated lesion) Yes 100% 100% Yes
Day 90: <100% re-epithelization (ulcer) or flattening (non-ulcerated lesion) Yes 100% 100% Yes
Other efficacy parameters: stigma and cosmetic
Presence and grading of scar NA 100% 100% Yes
 Depending on known side effect, safety profile, phase of development, drug class and route of administration
 Will require standardization
https://doi.org/10.1371/journal.pntd.0006141.t001
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While it was acknowledged that, in some instances, treatment is provided until the lesion
is considered cured (especially when evaluating topical or intralesional treatments), efforts
should be made to report the number of cured subjects at day 42 and the initial cure at day 90.
Final cure should be assessed at Day 180 (6 months after initiating treatment); a 12-month
follow-up was not deemed necessary. Nevertheless, NWCL participants identified the need to
assess the ideal time of follow-up for final cure, and document the rate of late-responses and
relapses between days 90–180 (3–6 months). This would provide important elements to under-
stand the cost-effectiveness of a 6-month follow-up, and inform study design.
There was almost general agreement that time of follow-up is counted starting from the
first day of treatment and not from the end of treatment. The main issue was how to deal with
treatments of different duration. For instance, systemic antimonials are given for 14–30 days
(see Tables 2 and 3); an initial assessment at day 42 counting from treatment start means 12–
15 to 28–31 days after the end of treatment, compared to e.g. thermotherapy, which may be
given in one single treatment.
It was also agreed that treatment failure should be defined at Day 42 as less than 50% re-epi-
thelialization (if an ulcer) or flattening (if a non-ulcerated lesion); and at Day 90 as less than
100% re-epithelialization or flattening, respectively.
Fig 1. Days counted from day treatment started.
https://doi.org/10.1371/journal.pntd.0006141.g001
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Table 3. Site characteristics in New World settings.
Country Bolivia Brazil Brazil Colombia Colombia Guatemala Panama Peru Venezuela
Institution Fundación
Nacional de
Dermatologı́a,
FUNDERMA.
Santa Cruz de
la Sierra
Serviço de
Imunologia,
Federal
University
of Bahia
Centro de
Pesquisa
René Rachou
—FIOCRUZ,
Belo
Horizonte
Centro
Internacional
de
Entrenamiento
e
Investigaciones
Médicas
(CIDEIM), Cali
Programa de
Estudio y
Control de
Enfermedades
Tropicales
(PECET),
Medellı́n
Center for
Health
Studies,
Universidad
del Valle de
Guatemala
Instituto
Conmemorativo
Gorgas de
Estudios de la
Salud, Panamá
Hospital
Cayetano
Heredia,
Universidad
Peruana
Cayetano
Heredia,
Lima
Instituto de
Biomedicina
Dr Jacinto
Convit.
Caracas
Venezuela
Area of work Santa Cruz
and referred
patients
Corte de
Pedra,
Tancredo
Neves, Bahia
Minas Gerais Mainly South-
western
Caribbean
coast,
Amazon,
Andean
valleys, Pacific
coast and
eastern plains
El Peten and
Alta Verapaz
Panama City
and refereed
patients
Andean and
jungle areas
Metropolitan
area
Primary or
referral center
referral both referral both referral referral referral referral referral
Clinical
research
(GCP)
experience
yes yes yes yes yes yes yes yes yes
National
treatment
guidelines
yes yes yes yes yes yes yes yes yes
N. of cases in
country/
(WHO official
figures
1683 19402 11433 254 1581 5888
(investigators
estimate up to
8000)
1661
Number of
cases seen per
year
150–200 800–1,500 ~90 ~200 200 ~100 ~100 350–400 150
Leishmania
species
L. braziliensis,
L. guyanensis,
L. mexicana
L.braziliensis L.braziliensis
(95%)
L. panamensis,
L. braziliensis,
L. guyanensis
L.panamensis,
L.braziliensis
L.
braziliensis,
L. mexicana
L. panamensis, L.
guyanensis, L.
braziliensis
L. braziliensis,
L. peruviana,
L. guyanensis
L. braziliensis
and L.
mexicana
Type of
diagnosis,
species
identification
direct smear;
capability for
culture and
PCR
PCR direct smear direct smear,
PCR, biopsy,
monoclonal
antibodies and
isoenzymes
direct smear,
PCR
direct smear,
PCR
direct smear,
culture, PCR,
DTA
direct smear,
PCR, culture;
species
identification
direct smear,
culture, PCR,
biopsy
Age of
subjects
young adults mainly
adults
young adults adults and
children
adults and
children
adults and
children
adults and
children
adults and
children
adults
Gender (F:M) 10:90 30:70 30:70 20:80 50:50 (civilian
population)
1:99 (military
population)
45:55 33:67 50:50 38:62
Emerging or
stable foci
stable stable stable stable stable stable stable stable stable
Rural or (peri)
urban setting
both rural peri-urban rural both rural both rural both
Seasonality all year-round all year all year-
round
year-round All year-round all year-
round
peak: March to
July
peak:
January-June
all year-round
Number of
lesions
1–2 single 70% single 1 (1–3) 2 1–2 2–3 80% single 1–2
Type of lesion
and size
ulcer; 25–30
mm
90% ulcer;
15 mm
70% ulcer;
80%<40 mm
80% ulcer; 90%
<50 mm
diameter
mainly ulcer
(~80%); 20
mm
90% ulcers;
10–20 mm
90% ulcer; 10–20
mm
80% ulcer;
70% <30 mm
80% ulcer; 70%
<30 mm
(Continued)
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It was suggested that the presence and grading of scars (cosmetic effects) should be assessed
in a standardized way and included in future long-term treatment evaluation, as this repre-
sents an important parameter for patients because of the related stigma and social conse-
quences. The results of qualitative studies using in-depth semi-structured CL patient
interviews aimed at understanding the CL patient’s needs and expectations from treatment
(paper in preparation) will also help inform study design.
CL trial site characteristics and capacities
Site characteristics for OWCL and NWCL are summarized in Tables 2 and 3 respectively.
About the sites. ‘Site’ here refers to a single or multiple treatment sites with different
catchment areas covered by one group. Of the OWCL sites, 3 are referral centers, 2 primary
and 5 both; for NWCL, 7 are referral and two both primary and referral. Capacity for good
clinical practice (GCP) trials exists in 8/10 OWCL sites and 9/9 NWCL sites.
About the disease: OWCL. Species and diagnosis: Cases of both L. major and L. tropica
cases are seen at 6/10 sites (one also L. infantum), while 2 sites have one species each and 2
have L. aethiopica. Parasitological diagnosis by direct smear is done at all sites. Capacity for
polymerase–chain reaction (PCR) exists at 8 sites and culture at 5, though techniques are not
always used routinely.
Age and Sex: All ages are affected in 7/10 sites. L. aethiopica affects mostly older children,
adolescents and young adults. OWCL affects equally women and men, with more men being
seen only in Iran.
Endemicity: Six out of 10 sites have stable transmission, while 4 see patients from both
emerging and stable foci. There is no obvious pattern relating age and transmission. Burkina-
Faso has a stable focus in Ougadougou and a newer one in Bobo-Dioulasso.
Setting: Patients seen at 6/10 sites are from both rural and periurban settings. In Burkina-
Faso the Ougadougou focus is periurban, while the one in Bobo-Dioulasso is rural.
Table 3. (Continued)
Country Bolivia Brazil Brazil Colombia Colombia Guatemala Panama Peru Venezuela
Duration of
lesion
3–5 months in
90% cases
mean 1.5
month
~3 months ~2 months 2 months 3–4 months 3–4 weeks mostly <3
months
1 month
Other
manifestations
lymphangitis
(35%), MCL
(3–15%), DCL
(5%)
MCL (3%),
DCL(4%),
atypical
(3%)
lymphangitis
(10–15%)
lymphangitis
(18%), mucosal
involvement
(4%),
disseminated
(sporadic)
lymphangitis,
MCL
lymphangitis
(5%)
lymphangitis
(10–20%)
lymphangitis
(20–30%)—
depending on
time of
disease
lymphangitis
(<10%)
Treatment
(type/dose)
IM
antimonials 20
mg/kg/d x 20
d (85%);
amphotericin
B 0.5–1 mg
(15%)
IM
antimonials
20 mg/kg/d
x 20 d
IL
antimonials
(60%); IM
antimonials
20 mg/kg/d x
20 d (40%)
IM antimonials
20 mg/kg/d x
20 d. oral
miltefosine
(1.5–2.5 mg/kg/
day);
thermotherapy
IL antimonials
IM
antimonials:
20 mg/kg/day
x 20d oral
miltefosine 2.5
mg/kg/day x
28d
pentamidine:
3–4 mg/kg/d x
3 doses every
other day
IM
antimonials
20 mg/kg/d x
20 d
IM antimonials
20 mg/kg/d x 20
d; amphotericin
B for rescue
treatment
IM
antimonials
20 mg/kg/d x
20 d,
amphotericin
B rescue
treatment
IM
antimonials, no
exact dose
recommended;
oral miltefosine
Duration of
follow up
6 months 6 months 12 months 6 months 6 months 3–6 months 3–6 months 12 months 5 years
https://doi.org/10.1371/journal.pntd.0006141.t003
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Seasonality: Cases are seen mostly in fall and winter at 7/10 sites with variable durations.
Year-round transmission occurs in Ethiopia.
Number of lesions: Patients tend to present with few (1–2) lesions at 4 sites. Several lesions
(>5) are seen in Afghanistan (L. tropica) and Burkina-Faso (L. major). The number of lesions
varies in Iran and Morocco. There is no obvious pattern relating species and number of
lesions.
Morphology and duration of lesions: Ulcerated, papular and nodular forms are seen across
all sites. Lesions are up to 40 mm at 4 sites and up to 20 mm in 2 other sites. Other manifesta-
tions include disseminated (DCL, 5 sites), and others like lupoid, erysepeloid, sporotrichoid. L.
aethiopica manifestations include DCL and mucocutaneous (MCL) forms.
Patients present with lesions that have lasted variably from weeks to years across the various
sites. Tunisia and Morocco report that L. major patients seek treatment when lesions have
been present for up to 6 months, L. tropica’s 12 months.
About the disease: NWCL. Species and Diagnosis: L. braziliensis is the most frequent spe-
cies in 6/9 sites and present also in the other 3, where L. panamensis predominates. Other spe-
cies found are L. mexicana and L. guyanensis. Parasitological diagnosis by direct smear is the
technique used at all but one site in Brazil. Polymerase–chain reaction (PCR) exists at 8 sites
and culture at 4 but these are not always done routinely.
Age and Sex: All ages are affected in 5/9 sites. Men represent approximately two-thirds of
patients at 5 sites and 90% at another one, while the other 3 sites have almost equal representa-
tion of women and men.
Endemicity: All sites have stable transmission
Setting: Patients seen at 4/9 sites are from both rural and periurban settings, 4 rural and one
periurban.
Seasonality: Cases are seen all year-round in all sites, some with seasonal peaks.
Number of lesions: Patients tend to present with single or few (up to 3) lesions.
Morphology and duration of lesions: Ulcerated lesions predominate at all sites. Other mani-
festations include lymphangitis (5–35% at 8/9 sites), MCL (3 sites) and DCL (2 sites).
Patients present with lesions that have lasted from 3 weeks to 5 months, but mostly not
exceeding 3 months (7 sites). Bolivia reports seeing increasing numbers of chronic cases with
disease lasting for over 18 months.
About treatment and follow-up: OWCL. Treatment: Intramuscular (IM) antimonials at
20 mg/kg/day for 14–30 days is used at 8/9 sites. Intralesional (IL) antimonials are also used
at 7 sites at variable dosages (volume injected, number of doses, and duration of treatment).
Choice of treatment may depend on the number of lesions (IL if less than 5 lesions, otherwise
IM in Burkina-Faso) or species (IM antimonials are given daily for 14 days in case of L. major
and 21 if L. tropica at one site in Iran). In addition, local antiseptics are regularly applied at 2
sites. Cryotherapy and/or thermotherapy are also used at 5 sites (alone or combined with IL
injections). Other medications available are liposomal amphotericin B (2 sites in Iran), paro-
momycin and oral miltefosine at one site in Ethiopia.
Duration of follow-up: Practice varies greatly; 3 sites follow patients up routinely until com-
plete healing of lesions; others follow patients up for a fixed duration from 1 month to 12
months (3–6 months in 4 sites).
About treatment and follow-up: NWCL. Treatment: Intramuscular (IM) antimonial at
20 mg/kg/day for 20 days is used at all sites. Second-line treatment consists of amphotericin B
deoxycholate at 3 sites, oral miltefosine (2 sites), or pentamidine (1 site). Intra-lesional antimo-
nials are used only in one site in Colombia and one in Brazil.
Duration of follow-up: Six (6) sites follow patients up for 6 months, 2 for 12 months, and
one for 5 years.
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Discussion
The consensus reached among participants during the two meetings allows standardization of
future clinical research across OWCL and NWCL sites—a major issue which has hampered
our collective ability to generate strong evidence for treatment guidelines and policy. We
encourage CL researchers to adopt and adapt if so required the proposed parameters and out-
comes in their future trials. Furthermore, the expertise afforded between the two sets of clinical
sites provides the basis for a powerful consortium with potential for extensive, standardized
assessment of interventions for CL.
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7. González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cuta-
neous and mucocutaneous leishmaniasis. Cochrane Database of Systematic Reviews, 2009; Issue 2.
Art. No.: CD004834. https://doi.org/10.1002/14651858.CD004834.pub2 PMID: 19370612
8. Reveiz L, Maia-Elkhoury AN, Nicholls RS, Romero GA, Yadon ZE. Interventions for American cutane-
ous and mucocutaneous leishmaniasis: a systematic review update. PLoS One. 2013; 29; 8(4):e61843.
https://doi.org/10.1371/journal.pone.0061843 PMID: 23637917
Clinical trial methodologies for CL
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006141 January 12, 2018 11 / 12
9. Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, Magill A, Lapujade O, Buffet P, Alvar J. Methodol-
ogy of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis.
2013; 7(3):e2130. https://doi.org/10.1371/journal.pntd.0002130 PMID: 23556016
10. Rede de Pesquisadores e Colaboradores em Leishmanioses, Rede Leish web Page link: http://www.
dndial.org/pt/doencas-negligenciadas/leishmanioses/redeleishprincipal.html
Clinical trial methodologies for CL
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006141 January 12, 2018 12 / 12
